Background: Complement C3 has been shown to be highly expressed in cutaneous
Inflammatory processes and factors are activated in cSCC tissues and pathogenesis. 7 The complement system is a critical part of innate immunity against pathogen invasion. This system activates through the classical, alternative and lectin pathways, during which a cascade of enzymatic reactions stimulate multiple proteins. 8 Recently, the role of the complement pathway in cancer growth has been elucidated. Complement anaphylatoxin (C3a), which is the active form of C3, and C3a receptor signalling could promote melanoma development and growth. 9 Binding of C3a with its receptor negatively regulates E-cadherin expression, which promotes the invasive phenotype in tumour cells. 10 Other complement factors have been implicated in lung, 11 breast, 12 colon 13 and pancreatic cancers. 14 In cSCC tissues, complement factor H expression increased the growth and migration advantage of cSCC cell lines, whereas silencing complement factor H expression reduced this growth and migration. 15 C3 expression was upregulated more in primary and metastatic CSCC cells than in normal epidermal keratinocytes. 15 Nevertheless, the role of C3 in cSCC remains unknown.
Sex determining region Y-Box 2 (Sox2) is a member of the SOX family. It contains a high-mobility domain, which can bind specifically to a DNA sequence and regulate downstream gene expression. Sox2
maintains cell stemness and is essential in induced pluripotent stem cells. 16 Alterations in Sox2 expression cause developmental diseases, 17 and amplification of Sox2 occurs in many cancers. High expression of Sox2 is critical for maintaining cancer stem cells. 18 Ectopic Sox2 expression also reduces tamoxifen sensitivity in cancer cells. 19 Several factors regulate Sox2 expression at the transcriptional level in mouse and human cSCC. Deletion of Sox2 causes cSCC tumour regression and malignant transformation. 20 Sox2 expression regulates the Nrp1 and vascular endothelial growth factor (VEGF) pathway, which causes cSCC proliferation by facilitating tumour-initiating cells to generate more undifferentiated tumour cells. 21 The current study sought to explore the role of C3a in cSCC and its association with Sox2. The results indicate that the complement system plays a role in cSCC carcinogenesis and thus is a potential target for tumour therapy.
| MATERIALS AND METHODS

| Cutaneous squamous cell carcinoma culture and treatment
The cSCC cell lines HSC-1 and HSC-5 were obtained from the Japa- were incubated for 48 hours in a 5% CO 2 atmosphere at 37°C. After the transfection, western blotting was used to examine the transfection efficacy.
| Cell viability
A431 and SCC13 cell viability was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay.
Cells were placed in 96-well plates (1 × 10 5 cells per mL) and treated as indicated. The medium was then removed and changed into normal Eagle's MEM with 10% FBS for another 24-hours culturing.
The determination of cell viability was carried out according to the manufacturer's protocols (#ST316; Beyotime, Jiangsu, China). After incubation for 4 hours, DMSO (150 μL per well) was added to end the reaction and the absorbance was determined in an ELISA plate reader at 570 nm at the indicated time. 
| Cell migration
| Real-time quantitative PCR
The cSCC cells or frozen homogenized tumour tissues and total RNA were extracted with an RNeasy kit (Qiagen, Hilden, Germany) according to manufacturer instructions. RNA concentrations were detected with a Nanodrop 2000 (ThermoFisher Scientific, Shanghai, China) and purified with an RNA purification kit (Tiangen, Beijing, China). The first strand of cDNA was synthesized using a OneStep RT-PCR Kit (Qiagen). Quantitative PCR then was conducted using a SYBR Green PremixEx Taq (Takara, Dalian, China). Primers used in the reactions were listed in Table 1 . Data were analysed via the delta/delta cycle threshold (CT) method. Horseradish-peroxidase-conjugated secondary antibody was then added, and cells were incubated for 2 hours at room temperature.
Signals of target protein were visualized by incubating the membranes with chemiluminescence reagents and then quantifying with the ImageJ program (National Institutes of Health, Bethesda, MD, USA). Β-actin was used as the loading control for normalization.
| Immunohistochemistry analysis
Tumour tissues were fixed by formalin, embedded by paraffin and cut into sections (4 μm thickness). The sections were then deparaffinized, rehydrated, immersed in 3% hydrogen peroxide solution for 10 minutes, boiled in citrate buffer (pH 6.0) for 5 minutes and then cooled at room temperature for 2 hours. Following that, the sections were blocked with 5% BSA to reduce non-specific antibody binding.
Rabbit antibodies against β-catenin, and Sox-2 were then used to detect target protein expression (4°C overnight). The bound antibodies were then detected using the GTvision two-step histostaining reagent (Genetech, Shanghai, China) and DAB (3,3′-diaminobenzidine tetrahydrochloride) substrate.
F I G U R E 6
The effect of C3 on cSCC cell growth in mouse model. (A) C3aR was knocked down in A431 cells and then subcutaneously implanted into nude mice. Body weights were measured every week since the implantation. n = 5-6. *P < 0.05 vs control. (B) Tumour volumes were measured by caliper and calculated using the formula V = (length × width2)/2. n = 5-6. *P < 0.05 vs control. (C) At 4 weeks after the implantation, xenografts were harvested and the expression of β-catenin and Sox-2 was detected by immunohistochemistry. Scale bar = 20 μm. n = 5-6
| Statistical analysis
Obtained data are expressed as mean ± SD. One-way ANOVA was employed to compare the difference among multiple groups. Statistical software SPSS 13.0 (SPSS Inc., Chicago, IL, USA) was used for data analysis and comparison. P-values less than 0.05 were considered significant.
| RESULTS
| C3 was highly expressed in tumour cell lines
We compared the expression of C3 mRNA in a series of cSCC cell Figure 2C,D) . Activation of matrix metalloproteinases contributed to extracellular matrix remodelling and facilitated cancer cell metastasis. We also observed elevated expression of pro-matrix metalloproteinase 1 (pro-MMP1) and pro-matrix metalloproteinase 2 (pro-MMP2) expression in cSCC cells that were exposed to C3a ( Figure 2E,F) . However, the C3aR antagonist decreased C3a-induced expression of pro-MMP1 and pro-MMP2 ( Figure 2E,F) .
| C3a treatment potentiated stemness factor expression in cutaneous squamous cell carcinoma
A previous study has linked complement factors with tumour growth and stemness in cancer cells. 24 Given that C3a prompted cSCC cell proliferation and migration, we explored whether C3a influenced stemness factors Sox-2, Nanog, Oct-4, c-Myc and CD-44. In comparison with the control, C3a caused significant elevation of mRNA in Sox-2, Nanog, Oct-4, c-Myc and CD-44, which was lowered by C3aR blockade ( Figure 3A ,B).
To examine the functions of stemness factors in cSCC malignant transformation, we silenced the expression of Sox-2, which is the most upregulated stemness factor ( Figure 3A and HSC-1 cells than in HaCaT keratinocytes. 15 Hence, these cell lines may be appropriate to mimic the pathogenesis of cSCC and to explore the role of C3 in cancer cells. This study used A431 and SCC13 cells for analysis, as C3 expression is highest in these two cell lines.
When C3 encounters its convertases (C3bBb and C4b2a) and is activated following protein cleavage, complement anaphylatoxin C3a is secreted and exerts various functions in animal cells through C3aR. 27 In this study, we found that different doses of C3a increased cell viability, promoted cyclin D1 and cyclin E expression, and stimulated cell migration in cSCC cell lines. The effect of C3a could be antagonized by blocking C3aR with its specific antagonist, which suggests that C3aR activation may be required for cSCC cell transformation. C3aR is ubiquitously expressed in many tissues like the bone marrow, 28 brain, 29 heart 30 and skin. 31 Interestingly, C3aR blockade has been shown to suppress C3 activation in mouse lungs, suggesting a dependence on C3aR in C3a production. 32 Our results showed that the C3aR antagonist decreased cancer cell proliferation and migration, compared with the control without C3a treatment. These findings indicate that C3aR participates in complement autoactivation.
Angiogenesis mediated by VEGF is essential in solid tumour progression. In poorly differentiated cSCC, VEGF is reportedly highly expressed and correlated with p16 expression, which suggests an interaction between VEGF and p16 in the dedifferentiation of cutaneous tumours. 33 VEGF also has been implicated in tumour immune evasion by disabling myeloid dendritic cells. 34 Blocking neuropilin-1, which is a co-receptor of VEGF in cutaneous cancer stem cells, impedes cancer stemness and renewal. 35 Our study showed that are critical mediators in tumourigenesis and tissue remodelling because they degrade extracellular matrix. We found that C3a treatment promoted and C3aR blockade inhibited pro-MMP-1 and pro-MMP2 expression in cSCC cells. 7, 36 C3a plays a pivotal role in inducing retinal stem and progenitor cell activation, independent of fibroblast growth factor. 27 Another complement anaphylatoxin C5a and its receptor C5aR are expressed in human pluripotent stem cells, and they promote pluripotency of stem cells. 37 Stemness factors Sox-2, Nanog, Oct-4 and c-Myc control the self-renewal and pluripotency of human pluripotent stem cells, suggesting that they are correlated with cancer stem cells. 38 In this study, C3a exposure promoted the expression of Sox-2, Nanog, Oct-4, c-Myc and CD-44. Sox-2 disruption ablated cell proliferation and migration induced by C3a and inhibited VEGF and MMP expression. The study provides more evidence that C3a enhances the stemness of cSCC cells.
Activation of the Wnt and β-catenin pathway has been demonstrated in liver, pancreatic, ovarian, and colorectal and other cancers. 39 Here, we observed that C3a treatment augmented β-catenin 
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